|
Clinical utility of colon cancer molecular subtypes: Validation of two main colorectal molecular classifications on the PETACC-8 phase III trial cohort. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - Advanced Accelerator Applications |
Travel, Accommodations, Expenses - Amgen; Bayer; IPSEN; Novartis |
|
|
Honoraria - Amgen; Merck Serono |
|
|
Consulting or Advisory Role - Amgen; Merck Serono |
Speakers' Bureau - Amgen; Novartis; Roche |
|
Travel, Accommodations, Expenses - Amgen; Merck; Novartis; Roche |
|
|
|
Consulting or Advisory Role - Meyer; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
Dominique Esperance Guenot |
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Celgene; Lilly; Merck; Novartis; Pfizer; Roche; Sanofi |
Research Funding - Merck Serono; Roche |
Travel, Accommodations, Expenses - Ipsen; Merck |
|
|
Consulting or Advisory Role - Amgen; Baxalta; Celgene; Lilly; Merck KGaA; Roche; SERVIER |
Speakers' Bureau - Amgen; Baxalta; Lilly; Merck; Roche/Genentech; Sanofi; SERVIER |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Lilly; Merck Serono; Roche |
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Lilly; Merck Serono; Roche |